Baseline Characteristics and Treatment Outcomes for Men with Acquired or Lifelong Premature Ejaculation with Mild or No Erectile Dysfunction: Integrated Analyses of Two Phase 3 Dapoxetine Trials

2010 ◽  
Vol 7 (6) ◽  
pp. 2231-2242 ◽  
Author(s):  
Hartmut Porst ◽  
Chris G. McMahon ◽  
Stanley E. Althof ◽  
Ira Sharlip ◽  
Scott Bull ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Treatment Outcomes ◽  
Premature Ejaculation ◽  
Phase 3 ◽  
Two Phase ◽  
Baseline Characteristics ◽  
Lifelong Premature Ejaculation

1198: A Novel Topical Alprostadil Cream for the Treatment of Erectile Dysfunction (ED): Combined Analysis of Two Phase 3 Pivotal Studies

2004 ◽  
Vol 171 (4S) ◽  
pp. 316-316
Author(s):  
Harin Padma-Nathan ◽  
Edward D. Kim ◽  
James G. McMurray ◽  
Denise Thwing ◽  
Jane Fendl ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Phase 3 ◽  
Two Phase ◽  
Combined Analysis

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies

2019 ◽  
Vol 3 ◽  
pp. S25
Author(s):  
Benjamin Ehst ◽  
George Han ◽  
Scott Guenthner ◽  
Kimberly Eads ◽  
Abby Jacobson
Keyword(s):  
Disease Duration ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Two Phase ◽  
Term Efficacy

Abstract not available.

Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2

2019 ◽  
Vol 3 ◽  
pp. S40
Author(s):  
P Van de Kerkhof ◽  
A Pinter ◽  
M Boehnlein ◽  
S Kavanagh ◽  
J.J. Crowley
Keyword(s):  
Clinical Trials ◽  
Head And Neck ◽  
Certolizumab Pegol ◽  
Phase 3 ◽  
Two Phase

Abstract not available.

Sign in / Sign up

Export Citation Format

Share Document